Recent Updates
Recently added Catalysts
MIRA Positive Sentiment

MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND

Tuesday, September 1, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MIRA Pharmaceuticals has reported positive outcomes from its recent toxicology studies of MIRA-55, an oral non-opioid drug candidate aimed at treating inflammatory pain. The studies, conducted over a 7-day period in rats and dogs, support the drug's advancement towards an Investigational New Drug (IND) application. This development marks a significant step in MIRA's clinical pipeline.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive results from toxicology studies in rats and dogs.
  • Advancement of MIRA-55 towards Investigational New Drug (IND) application.
  • Focus on non-opioid treatment for inflammatory pain.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+6%
120-day peak, hindsight
Typical move
0.6%
average across 2 past catalysts
Cash runway
~20 mo
Low dilution risk
Lead asset
Ketamir-2
Phase 1 · Healthy Adult Participants

Full Press Release Details

MIAMI, Sept. 01, 2026 (GLOBE NEWSWIRE) — MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”) , a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced positive results from completed 7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs. MIRA-55 is the Company’s investigational oral, non-opioid drug candidate being developed for inflammatory pain. Cross-Species Study Findings The com…
You can read the full content here
The post MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND appeared first on MIRA Pharmaceuticals, Inc. (MIRA) .

Frequently Asked Questions

What is MIRA-55?

MIRA-55 is an investigational oral, non-opioid drug candidate developed for inflammatory pain.

What were the results of the toxicology studies?

The studies showed positive results in both rats and dogs over a 7-day period.

What is the next step for MIRA-55?

MIRA-55 is advancing toward an Investigational New Drug (IND) application.

What type of pain does MIRA-55 target?

MIRA-55 is designed to treat inflammatory pain.

ShareAdd on Google
Tags: MIRA Viatris Investor Conferences Healthcare MIRA Pharmaceuticals MIRA-55 non-opioid inflammatory pain clinical trials
Last updated: Sep 1, 2026

Biotech snapshot

Cash runway
$8M liquidity · $0M/mo burn
~20 mo
Low dilution risk
Lead asset
Ketamir-2Phase 1
Healthy Adult Participants →

Catalyst track record

+6%
best trade around MIRA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for MIRA.

See every catalyst's timing & PoA →